Cross-Sector entity
Of the tracked stories, 9 of 19 also mention Weiss Ratings, the most common co-covered peer. Across an 80-day span, the pace is roughly 1.7 stories per week. The busiest single day carried 3. markets accounts for 8 of the 19 tracked stories, while 6 other categories carry the remainder.
19 verified stories tracked
Last mentioned: 4d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 11 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 9 of 19 also mention Weiss Ratings, the most common co-covered peer. Across an 80-day span, the pace is roughly 1.7 stories per week. The busiest single day carried 3. markets accounts for 8 of the 19 tracked stories, while 6 other categories carry the remainder. Negative sentiment appears in 0% of the tracked stories. Piper Sandler appears in 19 tracked Cross-Sector stories published from June 22, 2026 through September 9, 2026. Each carries 2.1 original sources on average.
Computed from the 19 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Piper Sandler. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen rating actions
Wall Street Zen upgraded Tenaya from strong sell to sell and argenx from hold to buy.
Deutsche Bank downgrades argenx
Deutsche Bank cut argenx from buy to hold.
Insider Filings Publicized; Shares Fall 3%
Form 4 filing disclosed; MRCY shares trade down $2.87 midday to $91.36 on 1.12M shares vs average 675,344.
Farnsworth Sells $645,794.04 in MRCY Stock
EVP David Farnsworth sells 6,612 shares at average $97.67, reducing direct ownership by 5.31% to 117,967 shares.
MRCY Reports Mixed Q4; Ratner Sells Shares
Mercury Systems posts EPS of $0.37 vs $0.38 consensus and revenue of $289.78M vs $266.09M. EVP Steven Ratner sells 1,971 shares at $111.36 for $219,490.56 to cover tax withholding.
Truist raises argenx target
Truist Financial lifted its argenx target from $1,030.00 to $1,095.00 with a buy rating.
Tenaya Q2 miss
Tenaya reported EPS of -$0.20 versus -$0.07 expected and revenue of $1.11 million versus $10 million consensus.
Weiss Ratings upgrades Tenaya
Weiss Ratings moved Tenaya from sell (e+) to sell (d-), still within sell territory.
Baird raises argenx target
Robert W. Baird raised argenx target from $867.00 to $932.00 with a neutral rating.
Quarterly earnings released
SMBC reports EPS of $1.83 vs. $1.52 estimate, revenue of $51.77M.
argenx Q2 beat
argenx reported EPS of $7.32 versus $5.86 expected and revenue of $1.54 billion.
Wells Fargo Cuts Target to $70
Wells Fargo & Company lowers Freshpet’s price target from $75.00 to $70.00, keeping an Overweight rating, implying 28.42% upside.
BofA lifts argenx target
Bank of America raised its price objective on argenx from $1,016.00 to $1,088.00 with a buy rating.
Stephens reiterates Overweight rating
Stephens restated its Overweight rating and $40 price target, implying 8.78% upside.
Bank of America Lowers Target
Bank of America reduces its price target from $75.00 to $70.00 and maintains a Neutral rating.
Piper Sandler adjusts PT
Piper Sandler reiterates Neutral, boosts target from $71 to $79.
Piper Sandler Stays Overweight
Piper Sandler reaffirms an Overweight rating on Freshpet shares.
Wall Street Zen upgrades to Hold
Wall Street Zen upgraded PZZA from Sell to Hold.
Insider sale by EVP Windes
EVP Richard Windes sells 2,000 shares at average $69.70, totaling $139,400.
Weiss Ratings reiterates Buy
Weiss Ratings issues a 'buy (b)' rating on SMBC.
A Sunday morning research note lifted Wall Street Zen's view on two biotechs—argenx to buy and Tenaya from strong sell to sell—but the market implications diverge sharply. Finance readers get a comparison of a profitable $63 billion rare-disease leader trading at a 38.67 P/E against a $148.75 million speculative gene therapy name at -1.25 P/E.
Wall Street Zen upgraded Tenaya from strong sell to sell, but the micro-cap gene therapy company still trades near a 52-week low after a sharp Q2 EPS and revenue miss. Biotech readers get a closer look at how clinical-stage execution failures are reflected in rating actions, while argenx's profitable rare disease business shows what commercial success looks like.
Source: tickerreport.com · dailypolitical.com
Tuesday's midday tape lifted MARA 4.6% to $11.83 and Sterling Infrastructure 3.2% to $502.20, but the more important signal for investors is a multi-week pattern of analyst price-target cuts. MARA's consensus target of $18.78 implies large upside yet carries 5.32 beta and negative earnings; STRL's $690.33 target still sits 37% above its price but below prior $900-plus targets. Finance readers should weigh consensus 'Moderate Buy' labels against balance-sheet and technical risks.
Source: themarketsdaily.com · tickerreport.com
Hollencrest Capital Management nearly exited UNH in Q2 2026, but much larger institutions piled in. Analysts remain bullish with price targets up to $490. For finance readers, the 13F reveals a rotation in shares rather than a fundamental warning.
Source: Ticker Report · Daily Political
Two Mercury Systems EVPs disclosed sell-to-cover trades totaling about $865K after an EPS miss of $0.01 and revenue beat. The transactions were driven by tax withholding on vested awards, but the stock's slide below moving averages adds pressure. Investors should separate mechanical insider flows from fundamental margin challenges.
Source: MarketBeat · themarketsdaily.com
Institutional 13F data shows new accumulation in Chubb as small advisory firms added positions from Q4 2025 through Q2 2026. Analyst targets range from $301 to $386, while insider sales and 83.81% institutional ownership frame a mixed but liquid market for CB.
Source: Ticker Report · Daily Political
Wells Fargo lowered Check Point's target to $130, highlighting a divided analyst community with an average target of $149.48. The stock's depressed valuation and low beta present a potential value opportunity against high-growth cyber peers.
Source: dailypolitical.com · themarketsdaily.com
Benchmark boosted outlooks on two disparate stocks—First Internet Bancorp and DexCom—offering a stark contrast in risk/reward. While INBK promises 21.74% upside based on the new $35 target, DXCM’s $82 target sits slightly below its trading price, highlighting valuation concerns despite a Buy rating.
Source: dailypolitical.com · themarketsdaily.com
Collegium Pharmaceutical's Q2 2026 earnings beat signals sustained demand for its abuse-deterrent pain medications. Revenue grew 6.3% to $199.88M, and EPS of $1.92 surpassed forecasts by $0.20, indicating commercial strength despite regulatory pressures.
Collegium Pharmaceutical delivered an 11.6% EPS beat and modest revenue beat, lifting shares to $29.47. High ROE and institutional accumulation offset by high leverage and mixed analyst ratings create a nuanced investment case.
Collegium Pharmaceutical's earnings beat of $0.20 per share, reaching $1.92 on $199.88M revenue, highlights its commercial success in the abuse-deterrent opioid space, a key sector for the biopharma industry.
Source: dailypolitical.com · themarketsdaily.com
Southern Missouri Bancorp delivered a strong quarter with earnings of $1.83 per share, beating estimates by $0.31 on revenue of $51.77 million. However, the stock fell 1.4% to $75.41 as analysts remain divided and insider selling raises questions.
Source: MarketBeat · tickerreport.com
WaFd (WAFD) reported quarterly EPS of $0.81, missing consensus by 2.4%, while the stock trades near a 52-week high and offers a 2.7% dividend yield. Analysts are split between hold and buy, and an insider sale adds caution. For income-focused investors, the small miss may be overshadowed by the stable payout and institutional accumulation.
Source: MarketBeat · themarketsdaily.com
Coinbase’s total trading volume is forecast to plunge 44% to $669 billion in 2026, yet analysts at William Blair see a sharp recovery in 2027 as Bitcoin stabilizes. The exchange’s push into Base layer-2, perpetual futures, and prediction markets adds new revenue drivers for the next cycle.
Despite a 34% cut to adjusted EBITDA estimates, Coinbase stock rallied on an Outperform rating from William Blair, signaling that the worst may be priced in. The firm expects a 44% drop in 2026 trading volumes before a rebound, while Piper Sandler lowered its target but remained neutral.
Source: finance.yahoo.com · Decrypt
Wells Fargo lowered its price target on Freshpet to $70 from $75 while maintaining an Overweight rating, implying the stock is undervalued by 28%. The market remains skeptical with FRPT trading at $54.51, well below the consensus analyst target of $74.25. Analysts overall rate the pet food company a Moderate Buy, despite a string of recent target cuts.
Source: Watch List News · Ticker Report
Stephens reiterated an Overweight rating on Papa John's with a $40 target, signaling an 8.78% upside. The Hold consensus and mixed analyst views reflect retail headwinds for the pizza chain amid fierce QSR competition and shifting consumer spending.
Source: Zolmax · Daily Political
Piper Sandler initiated Toast with an Overweight rating and a $32 price target, highlighting the company's cloud-based restaurant management platform. The 29% upside reflects confidence in its modular SaaS model and growing ecosystem of integration partners like Cartwheel and Stream.
Piper Sandler launched coverage on Toast with an Overweight rating and $32 price target, citing the company’s enterprise deal with Hungry Howie’s and new market expansion. The cloud platform supports over 500 locations, signaling strong retail adoption and 29% upside potential.
Source: Insider Trading · Yahoo Finance
